Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Profit After Tax: 2021-2025

Historic Profit After Tax for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Profit After Tax fell 1.58% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 19.81%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.49% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Profit After Tax stood at -$1.7 million for Q3 2025, which was up 4.06% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Profit After Tax ranged from a high of -$338,391 in Q2 2023 and a low of -$7.9 million during Q2 2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Profit After Tax value was -$1.8 million (recorded in 2025), while the average stood at -$1.8 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Profit After Tax soared by 95.70% in 2023 and then tumbled by 479.84% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Profit After Tax (Quarterly) stood at -$3.0 million in 2021, then grew by 29.29% to -$2.1 million in 2022, then rose by 29.65% to -$1.5 million in 2023, then plummeted by 74.20% to -$2.6 million in 2024, then fell by 1.58% to -$1.7 million in 2025.
  • Its Profit After Tax was -$1.7 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.